论文部分内容阅读
我们收集当前几种有较好远期疗效药物的实验和最初临床经验,这些药物能很好地预防排斥反应,可能不久会作为免疫抑制剂而应用于临床。生物免疫抑制剂——单克隆抗体 OKT3,一种抗T细胞受体-/CD3-分子复合物的抗体,是临床上首先使用的有强效抗排斥作用的单克隆抗体中的典型代表。 OKT3可以修饰CD3分子和T细胞受体(一个功能单位)并使之进入细胞内,因而抑制抗原识别功能。给予首剂OKT3数分钟内CD3阳性细胞全部从血液中消失,而在治疗结束后的头3周才缓慢出现。所有其它T细胞标志,如CD2、CD4、CD8最初也消失,但在随后的治疗中又出现。
We collected several current trials and initial clinical experience with better long-term therapeutic drugs that are highly effective in preventing rejection and may soon be available as immunosuppressive agents in the clinic. Bioimmunosuppressant - monoclonal antibody OKT3, an anti-T cell receptor - / CD3-molecule complex antibody, is the first clinical use of a strong anti-rejection monoclonal antibody typical. OKT3 modifies the CD3 molecule and T-cell receptor (a functional unit) and allows it to enter the cell, thereby inhibiting antigen recognition. CD3-positive cells disappeared completely from the bloodstream within minutes after the first dose of OKT3 and only slowly appeared in the first 3 weeks after treatment was completed. All other T cell markers, such as CD2, CD4, and CD8, also disappeared initially but again in subsequent treatment.